Bioverativ Inc. (BIVV)

1,925.70
24.39 1.25
Prev Close 1,950.09
Open 1,930.24
Day Low/High 1,925.70 / 1,930.24
52 Wk Low/High 928.00 / 1,943.53
Volume 1.43K
Avg Volume 2.51M
Exchange n.a.
Shares Outstanding 108.16M
Market Cap 11.33B
EPS 3.30
Div & Yield N.A. (N.A)

Latest News

Bioverativ Reports Fourth Quarter And Full Year 2017 Performance

Bioverativ Reports Fourth Quarter And Full Year 2017 Performance

Bioverativ Inc. (NASDAQ: BIVV) today reported financial results for the fourth quarter and full year of 2017.

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Of Bioverativ Inc. In Connection With The Sale Of The Company To Sanofi

The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Of Bioverativ Inc. In Connection With The Sale Of The Company To Sanofi

The Law Offices of Vincent Wong are investigating the Board of Directors of Bioverativ Inc.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Bioverativ Inc. To Sanofi For $105 Per Share Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Bioverativ Inc. To Sanofi For $105 Per Share Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Bioverativ Inc.

Allergan and Energy Stocks Have Big Days

A flurry of high-priced merger-and-acquisition activity explains the move in Allergan.

Dow, S&P 500 and Nasdaq Post New Records as Senate Reaches Deal to End Shutdown

Dow, S&P 500 and Nasdaq Post New Records as Senate Reaches Deal to End Shutdown

Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Bioverativ Inc. To Sanofi For $105 Per Share Is Fair To Shareholders - BIVV

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Bioverativ Inc. To Sanofi For $105 Per Share Is Fair To Shareholders - BIVV

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Bioverativ Inc.

Dow, S&P 500 and Nasdaq Shake Off Government Shutdown to Trade Higher

Dow, S&P 500 and Nasdaq Shake Off Government Shutdown to Trade Higher

Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?

Will the Government Shutdown Kill the Mind-Blowing Bull Market?

Will the Government Shutdown Kill the Mind-Blowing Bull Market?

The stock market's impressive start to the year is at risk as the government shutdown enters day three. Meanwhile, a series of healthcare deals captivates Wall Street's attention.

The Government Shutdown May Actually Be a Positive for the Stock Market

The Government Shutdown May Actually Be a Positive for the Stock Market

There are 5 key factors that will impact stocks this week.

Government Shutdown and Everything Else You Need to Know Monday Morning

Government Shutdown and Everything Else You Need to Know Monday Morning

So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.

Sanofi Strikes $11.6 Billion Deal for Bioverativ

Sanofi Strikes $11.6 Billion Deal for Bioverativ

France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.

Bioverativ To Report Fourth Quarter And Year-End 2017 Financial Results On February 13, 2018

Bioverativ To Report Fourth Quarter And Year-End 2017 Financial Results On February 13, 2018

Bioverativ Inc. (NASDAQ: BIVV) today announced it will report fourth quarter and year-end 2017 financial results on Tuesday, February 13, 2018, after the market closes.

Bioverativ To Present At The 2018 J.P. Morgan Healthcare Conference

Bioverativ To Present At The 2018 J.P. Morgan Healthcare Conference

Bioverativ Inc. (NASDAQ: BIVV) announced today that it will present at the 2018 J.

Bioverativ Announces 2018 Annual Meeting Of Stockholders

Bioverativ Announces 2018 Annual Meeting Of Stockholders

Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, announced today that its 2018 Annual Meeting of Stockholders has been scheduled...

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Bioverativ's Investigational BIVV009 Demonstrates Safety, Tolerability And Efficacy In Phase 1b Clinical Trial In Cold Agglutinin Disease (CAgD) Patients

Bioverativ's Investigational BIVV009 Demonstrates Safety, Tolerability And Efficacy In Phase 1b Clinical Trial In Cold Agglutinin Disease (CAgD) Patients

Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today presented data demonstrating that BIVV009, its first-in-class...